Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc. News
Gyre Therapeutics, Inc. Quantitative Score
About Gyre Therapeutics, Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
Gyre Therapeutics, Inc. Earnings & Revenue
Gyre Therapeutics, Inc. Financials
Table Compare
Compare GYRE metrics with: | |||
|---|---|---|---|
Earnings & Growth | GYRE | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | GYRE | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | GYRE | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | GYRE | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Gyre Therapeutics, Inc. Income
Gyre Therapeutics, Inc. Balance Sheet
Gyre Therapeutics, Inc. Cash Flow
Gyre Therapeutics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Buy |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Gyre Therapeutics, Inc. Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 2.2390 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| TBA | 0.24 | Quarterly |
| TBA | 1.43 | Quarterly |
| TBA | 0.569 | Quarterly |
Gyre Therapeutics, Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Gyre Therapeutics, Inc. Executives
| Name | Role |
|---|---|
| Mr. Weiguo Ye | Chief Operating Officer |
| Ms. Ruoyu Chen | Chief Financial Officer |
| Dr. Han Ying Ph.D. | Chief Executive Officer & Director |
| Mr. Songjiang Ma | President & Director |
| Ms. Seline E. Miller CPA | Senior Vice President of Finance |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Weiguo Ye | Chief Operating Officer | Male | 1978 | 274.62K |
| Ms. Ruoyu Chen | Chief Financial Officer | Female | 1971 | 121.35K |
| Dr. Han Ying Ph.D. | Chief Executive Officer & Director | 1966 | 10.5K | |
| Mr. Songjiang Ma | President & Director | Male | 1956 | -- |
| Ms. Seline E. Miller CPA | Senior Vice President of Finance | Female | 1970 | -- |
Gyre Therapeutics, Inc. Insider Trades
| Date | 10 Jan |
| Name | Ma Songjiang |
| Role | President |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 1057 |
| Date | 13 Jan |
| Name | Ma Songjiang |
| Role | President |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 56 |
| Date | 3 Jan |
| Name | Ma Songjiang |
| Role | President |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 833 |
| Date | 6 Jan |
| Name | Ma Songjiang |
| Role | President |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 941 |
| Date | 7 Jan |
| Name | Ma Songjiang |
| Role | President |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 1275 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 10 Jan | Ma Songjiang | President | Disposed | S-Sale | 1057 |
| 13 Jan | Ma Songjiang | President | Disposed | S-Sale | 56 |
| 3 Jan | Ma Songjiang | President | Disposed | S-Sale | 833 |
| 6 Jan | Ma Songjiang | President | Disposed | S-Sale | 941 |
| 7 Jan | Ma Songjiang | President | Disposed | S-Sale | 1275 |